Business Context and Reporting Period
Company: iRhythm Holdings, Inc. (formerly iRhythm Technologies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Corporate Structure: On January 12, 2026, the company implemented a holding company structure. iRhythm Technologies, Inc. became a wholly-owned subsidiary of iRhythm Holdings, Inc. The financial statements reflect this reorganization as if it occurred at the beginning of the earliest period presented.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue, Net | $199,390 | $158,677 |
| Gross Profit | $141,353 | $109,216 |
| Gross Margin | 70.9% | 68.8% |
| Operating Loss | $(16,185) | $(32,556) |
| Net Loss | $(13,933) | $(30,700) |
| Adjusted EBITDA | $14,099 | $(2,635) |
| Cash & Cash Equivalents | $240,146 | $375,278 |
| Marketable Securities | $309,474 | $347,751 |
| Total Debt (Carrying Value) | $650,313 | $649,504 |
Liquidity: As of March 31, 2026, the company held $240.1 million in cash and cash equivalents and $309.5 million in marketable securities. Management believes current liquidity is sufficient for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 26% year-over-year to $199.4 million, driven by higher volume of iRhythm Services (Zio monitor and Zio AT) and improved contractual allowance reserves due to better market access and collection performance.
- Profitability Improvement: Net loss narrowed significantly by 55% to $13.9 million. Operating loss decreased by 50% to $16.2 million.
- Expense Trends:
- Selling, General & Administrative (SG&A): Increased 13% to $135.9 million, primarily due to higher legal fees for patent litigation ($3.7 million vs. $0.8 million) and provisions for credit losses.
- Research & Development (R&D): Remained relatively flat, decreasing 1% to $21.4 million.
- Cash Flow: Net cash used in operating activities increased to $26.2 million (from $7.9 million used in Q1 2025), largely due to timing of annual bonus payments and inventory purchases. Net cash provided by investing activities turned positive ($30.2 million) due to maturities of marketable securities exceeding purchases.
Outlook, Risks, and Contingencies
Management Commentary: The company continues to focus on improving gross margins and navigating macroeconomic headwinds. Revenue growth is attributed to existing and new account growth across third-party payors, CMS, and healthcare institutions.
Legal Proceedings & Contingencies:
- Patent Litigation: Ongoing lawsuits with Welch Allyn and Bardy Diagnostics (subsidiaries of Baxter International) alleging patent infringement. The company denies allegations and is actively defending. Litigation costs were a significant driver of SG&A increases.
- Securities Litigation: A putative securities class action lawsuit remains pending, with discovery ongoing and mediation discussions held in April 2026.
- Regulatory Investigations: The company is cooperating with the U.S. Department of Justice (DOJ) regarding subpoenas and civil investigative demands related to products and reimbursement claims. An appeal regarding document production privileges is pending before the Ninth Circuit Court of Appeals.
- FDA Compliance: The company is addressing observations from FDA inspections (Form 483) and a 2023 warning letter regarding quality systems and medical device reporting. Remediation activities are ongoing.
Risk Factors: Key risks include changes in Medicare reimbursement rates, potential denial of claims by payors, supply chain disruptions for single-source components, and the outcome of ongoing litigation and regulatory investigations.
Investor Verification Checklist
- Reimbursement Rates: Verify the impact of annual CMS reimbursement rate updates and any proposed Local Coverage Determinations (LCDs) on future margins.
- Legal Exposure: Monitor the status of patent litigation with Baxter subsidiaries and the securities class action for potential settlement costs or injunctions.
- Regulatory Status: Confirm the resolution of FDA Form 483 observations and the outcome of the DOJ document production appeal.
- Contractual Allowances: Assess the sustainability of the improved contractual allowance reserves reported in Q1 2026.
- Debt Covenants: Review the terms of the $661.3 million 1.50% Senior Convertible Notes due 2029, particularly regarding conversion triggers and potential dilution.